{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-086254","form_type":"8-K","ticker":"APRE","cik":"0001781983","company_name":"Aprea Therapeutics, Inc.","filed_at":"2026-07-23T20:05:20+00:00","discovered_at":"2026-07-23T20:06:00.275884+00:00","generated_at":"2026-07-23T20:06:11.530813+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aprea Therapeutics receives Nasdaq extension to Jan 19, 2027 to regain $1 minimum bid price compliance","bullets":["Received Nasdaq notification on July 23, 2026 granting additional 180-day compliance period until Jan 19, 2027.","Must achieve closing bid price of $1.00 for 10 consecutive business days during extension.","If not compliant by Jan 19, 2027, Nasdaq will issue delisting notice; company may appeal.","Previously reported deficiency notice on Jan 23, 2026; initial 180-day period expired July 22, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-086254","json":"https://secwatch.observer/filing/0001104659-26-086254.json","markdown":"https://secwatch.observer/filing/0001104659-26-086254.md","text":"https://secwatch.observer/filing/0001104659-26-086254.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781983/000110465926086254/0001104659-26-086254-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781983/000110465926086254/tm2621205d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-23T20:06:11.530813+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}